We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+15.75%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.54B
AUM Growth
+$40.4M
Cap. Flow
-$337M
Cap. Flow %
-21.88%
Top 10 Hldgs %
46.87%
Holding
259
New
90
Increased
52
Reduced
41
Closed
65

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$25.6M
2
TMP icon
Tompkins Financial
TMP
+$13.1M
3
AGEN
Agenus
AGEN
+$6.13M
4
MNKD icon
MannKind Corp
MNKD
+$5.33M
5
MDVN
MEDIVATION, INC.
MDVN
+$3.71M

Top Sells

Rank Stock Value
1
AEGR
Aegerion Pharmaceuticals
AEGR
+$28.4M
2
ABBV icon
AbbVie
ABBV
+$14.7M
3
ZTS icon
Zoetis
ZTS
+$14.2M
4
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$11.5M
5
ARWR icon
Arrowhead Research
ARWR
+$8.75M

Sector Composition

Rank Sector Weight
1 Healthcare 10.49%
2 Financials 0.07%
3 Technology 0.07%
4 Energy 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NKTR icon
126
PUT
Nektar Therapeutics
NKTR
$2.39B
$941K 0.06%
+60
New +$11.1K
HSTO
127
DELISTED
Histogen Inc. Common Stock
HSTO
$921K 0.06%
+458
New +$851K
IMUC
128
PUT
DELISTED
ImmunoCellular Therapeutics, Ltd.
IMUC
$914K 0.06%
+89
New +$9.77K
INFI
129
CALL
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$886K 0.06%
508
-158
-24% -$3.03K
ASTX
130
PUT
DELISTED
ASTEX PHARMACEUTICALS, INC COM
ASTX
$861K 0.06%
1,015
-28
-3% -$177
ASTX
131
DELISTED
ASTEX PHARMACEUTICALS, INC COM
ASTX
$845K 0.05%
+99,703
New +$631K
ACHN
132
PUT
DELISTED
Achillion Pharmaceuticals
ACHN
$802K 0.05%
2,654
+487
+22% +$3.34K
MDGL icon
133
CALL
Madrigal Pharmaceuticals
MDGL
$12.4B
$791K 0.05%
+36
New +$7.66K
MNTA
134
CALL
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$751K 0.05%
522
– –
FBIO icon
135
CALL
Fortress Biotech
FBIO
$113M
$748K 0.05%
71
+38
+115% +$4.66K
XOMA
136
PUT
DELISTED
Xoma
XOMA
$742K 0.05%
+83
New +$7.54K
ASTX
137
CALL
DELISTED
ASTEX PHARMACEUTICALS, INC COM
ASTX
$740K 0.05%
873
-1,434
-62% -$9.07K
ARAY icon
138
Accuray
ARAY
$29M
$739K 0.05%
100,000
+57,509
+135% +$363K
FRTX
139
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
$727K 0.05%
+185
New +$1.39M
VVUS
140
CALL
DELISTED
Vivus Inc
VVUS
$722K 0.05%
78
-126
-62% -$15.7K
TCRT icon
141
PUT
Alaunos Therapeutics
TCRT
$4.64M
$712K 0.05%
+12
New +$5.41K
IMNN icon
142
PUT
Imunon
IMNN
$6.43M
$710K 0.05%
+1
New +$14.8K
RIGL icon
143
Rigel Pharmaceuticals
RIGL
$712M
$710K 0.05%
+19,826
New +$724K
GERN icon
144
PUT
Geron
GERN
$930M
$697K 0.05%
+2,201
New +$3.61K
NSPH
145
DELISTED
NANOSPHERE INC. COM NEW
NSPH
$690K 0.04%
+17,256
New +$861K
IMNN icon
146
CALL
Imunon
IMNN
$6.43M
– –
-1
Closed -$14.8K
NKTR icon
147
CALL
Nektar Therapeutics
NKTR
$2.39B
$686K 0.04%
+44
New +$8.13K
DYAX
148
DELISTED
DYAX CORPORATION
DYAX
$682K 0.04%
+99,458
New +$452K
ARIA
149
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$581K 0.04%
+31,553
New +$613K
VVUS
150
PUT
DELISTED
Vivus Inc
VVUS
$572K 0.04%
61
-59
-49% -$7.37K
4 5
6
7 8

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q3 2013 Portfolio in Review

As of Q3 2013, Sabby Management held 259 positions worth $1.54B, up 2.7% from $1.5B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Sabby Management withdrew a net $337M in Q3 2013, closing 65 positions and reducing 41 holdings. Its most notable exit was AbbVie, an estimated $14.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 10% of assets, down from 11% a quarter earlier, followed by Financials and Technology.

Against the trend, Sabby Management opened a new position in Tompkins Financial worth $1.02M.

  • Sabby Management's largest Q3 2013 buy was Tompkins Financial: 288,454 shares worth $1.02M.
  • Sabby Management added most to Vertex Pharmaceuticals in Q3 2013, an estimated $25.6M increase.
  • Sabby Management's biggest Q3 2013 reduction was Aegerion Pharmaceuticals, cutting an estimated $28.4M.
  • Sabby Management fully exited AbbVie in Q3 2013, selling an estimated $14.7M.
  • Sabby Management's ten largest holdings make up 47% of its $1.54B portfolio in Q3 2013.
  • Sabby Management opened 90 new positions and closed 65 in Q3 2013.
  • Sabby Management's portfolio value rose 2.7% quarter-over-quarter to $1.54B.

Based on Sabby Management's 13F filing for Q3 2013, filed 14 Nov 2013.